CH
The startup specializes in non-invasive molecular diagnostics for high-mortality cancers through cell-free DNA testing that employs proprietary epigenomic analysis and big data techniques. This technology enables early cancer detection, allowing healthcare providers to implement curative therapies when treatment is most effective.
Updated 3 months ago
Funding
$85M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup specializes in non-invasive molecular diagnostics for high-mortality cancers through cell-free DNA testing that employs proprietary epigenomic analysis and big data techniques. This technology enables early cancer detection, allowing healthcare providers to implement curative therapies when treatment is most effective.